Drug information for VANTIN

Form Dosage Status Therapeutic Equivalence Active Ingred Ref. Sponsor Document
FOR SUSPENSION; ORAL EQ 100MG BASE/5ML Discontinued   CEFPODOXIME PROXETIL cefpodoxime proxetil PHARMACIA AND UPJOHN 50675
2007-06-07 Letter

2007-06-07 Label

2004-06-07 Label

2004-06-07 Letter

1999-07-27 Review

1998-11-20 Review

1998-11-20 Letter

1998-11-20 Letter
FOR SUSPENSION; ORAL EQ 50MG BASE/5ML Discontinued   CEFPODOXIME PROXETIL cefpodoxime proxetil PHARMACIA AND UPJOHN   "
TABLET; ORAL EQ 100MG BASE Discontinued   CEFPODOXIME PROXETIL cefpodoxime proxetil PHARMACIA AND UPJOHN 50674
2007-06-07 Letter

2007-06-07 Label

2004-06-07 Label

2004-06-07 Letter

1998-11-20 Letter

1998-11-20 Review
TABLET; ORAL EQ 200MG BASE Discontinued   CEFPODOXIME PROXETIL cefpodoxime proxetil PHARMACIA AND UPJOHN   "

Drug Adverse Effects information for VANTIN

Role code Indications Reaction # Reports
C OSTEOPOROSIS ASTHENIA 1
C OSTEOPOROSIS CAST APPLICATION 1
C OSTEOPOROSIS CHRONIC OBSTRUCTIVE PULMONARY DISEASE 1
C OSTEOPOROSIS COR PULMONALE 1
C OSTEOPOROSIS FEELING ABNORMAL 1
C OSTEOPOROSIS LEG AMPUTATION 1
C OSTEOPOROSIS MENTAL DISORDER 1
C OSTEOPOROSIS OVERDOSE 1
C OSTEOPOROSIS PERIPHERAL ARTERIAL OCCLUSIVE DISEASE 1
C OSTEOPOROSIS PERIPHERAL VASCULAR DISORDER 1
C OSTEOPOROSIS PLEURAL EFFUSION 1
C OSTEOPOROSIS PNEUMONIA 1
C OSTEOPOROSIS PULMONARY HAEMORRHAGE 1
C OSTEOPOROSIS WRONG TECHNIQUE IN DRUG USAGE PROCESS 1
Ads by Google